Saturn V Capital Management
$697M 13F equity value
24 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Saturn V Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| AMLX | AMYLYX PHARMACEUTICALS INC | 4,624,101 | $83M | 11.9% |
| ALMS | ALUMIS INC | 2,915,443 | $82M | 11.8% |
| ABVX | ABIVAX SA | 518,865 | $69M | 9.9% |
| PCVX | VAXCYTE INC | 852,914 | $50M | 7.1% |
| IMMX | IMMIX BIOPHARMA INC | 4,658,429 | $48M | 6.9% |
| PHVS | PHARVARIS N V | 1,314,122 | $45M | 6.5% |
| JAZZ | JAZZ PHARMACEUTICALS PLC | 160,938 | $39M | 5.6% |
| CELC | CELCUITY INC | 370,318 | $39M | 5.6% |
| IRON | DISC MEDICINE INC | 524,730 | $38M | 5.5% |
| CADL | CANDEL THERAPEUTICS INC | 3,303,686 | $34M | 4.9% |
Track Saturn V Capital Management's 13F portfolio: $697M in reported holdings, 24 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}